Evotec SE Share Price & Technical Analysis
EVO · $3.03 (+1.68%)
Healthcare / Drug Manufacturers - Specialty & Generic
$3.03
+1.68%
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammatio…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-3% return in May, 1% avg return in past 3 year May month.
5% return in 2026, -13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 16% | -3% | -24% | 19% | -3% | – | – | – | – | – | – | – | 5% |
| 25 | 5% | -2% | -23% | 24% | -5% | 8% | -5% | -12% | 3% | 11% | -20% | -6% | -24% |
| 24 | -33% | -3% | 5% | -33% | -10% | 2% | 0% | -19% | 3% | 8% | 21% | -9% | -67% |
| 23 | 23% | -9% | 17% | -13% | 18% | 2% | 18% | -11% | -17% | -10% | 15% | 19% | 52% |
| 22 | -15% | -29% | 7% | -21% | 17% | -12% | 4% | -17% | -18% | 9% | -12% | -13% | -100% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.06B
P/E ratio
—
52W high
$4.48
52W low
$2.31
Volume
39,161
Beta
1.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Evotec SE share price today?
- Evotec SE (EVO) last traded around $3.03 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does EVO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for EVO. Download the app for real-time alerts.
- How can I analyze Evotec SE stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.